CA2931161A1 - Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales - Google Patents

Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales Download PDF

Info

Publication number
CA2931161A1
CA2931161A1 CA2931161A CA2931161A CA2931161A1 CA 2931161 A1 CA2931161 A1 CA 2931161A1 CA 2931161 A CA2931161 A CA 2931161A CA 2931161 A CA2931161 A CA 2931161A CA 2931161 A1 CA2931161 A1 CA 2931161A1
Authority
CA
Canada
Prior art keywords
bladder
syndrome
pharmaceutically acceptable
patients
atopaxar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2931161A
Other languages
English (en)
French (fr)
Inventor
Bruno Le Grand
Didier Junquero
Nicolas MONJOTIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CA2931161A1 publication Critical patent/CA2931161A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2931161A 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales Abandoned CA2931161A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1362682 2013-12-16
FR1362682A FR3014693B1 (fr) 2013-12-16 2013-12-16 Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
PCT/EP2014/073453 WO2015090705A1 (fr) 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales

Publications (1)

Publication Number Publication Date
CA2931161A1 true CA2931161A1 (fr) 2015-06-25

Family

ID=50424483

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2931161A Abandoned CA2931161A1 (fr) 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales

Country Status (16)

Country Link
US (2) US9980970B2 (enExample)
EP (1) EP3082818A1 (enExample)
JP (1) JP6612233B2 (enExample)
KR (1) KR20160089518A (enExample)
CN (1) CN105813642B (enExample)
AU (1) AU2014365665B2 (enExample)
CA (1) CA2931161A1 (enExample)
FR (1) FR3014693B1 (enExample)
IL (1) IL246216A0 (enExample)
MA (1) MA39072A1 (enExample)
MX (1) MX370061B (enExample)
RU (1) RU2678309C1 (enExample)
SA (1) SA516371348B1 (enExample)
TN (1) TN2016000196A1 (enExample)
UA (1) UA120603C2 (enExample)
WO (1) WO2015090705A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3090317B1 (fr) * 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110393718B (zh) * 2019-08-20 2022-10-04 青岛海洋生物医药研究院 阿托帕沙溴酸作为新型jak-stat3信号通路抑制剂的用途和研究方法
FR3109089B1 (fr) * 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE378330T1 (de) 2002-04-16 2007-11-15 Schering Corp Trizyklische thrombin rezeptor antagonisten
CA2586344C (en) * 2004-11-04 2013-05-28 New England Medical Center Hospitals, Inc. G protein coupled receptor agonists and antagonists and methods of use
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
EP2709630A4 (en) * 2011-05-12 2014-10-22 UNIVERSITé LAVAL PAR1 HEMMER FOR USE IN THE TREATMENT OR PREVENTION OF PARAMYXOVIRIDAE INFECTIONS
RU2468759C1 (ru) * 2011-09-23 2012-12-10 Ольга Викторовна Тарабанова Способ лечения нарушений анатомических соотношений органов малого таза у женщин с атрофией мышц, поднимающих задний проход, и/или множественными дефектами ректо-вагинальной фасции

Also Published As

Publication number Publication date
AU2014365665B2 (en) 2019-08-29
MX370061B (es) 2019-11-29
US20180311253A1 (en) 2018-11-01
FR3014693A1 (fr) 2015-06-19
HK1221913A1 (zh) 2017-06-16
US9980970B2 (en) 2018-05-29
RU2678309C1 (ru) 2019-01-25
IL246216A0 (en) 2016-07-31
US20160287603A1 (en) 2016-10-06
WO2015090705A1 (fr) 2015-06-25
JP6612233B2 (ja) 2019-11-27
FR3014693B1 (fr) 2016-01-08
JP2016540799A (ja) 2016-12-28
US10265322B2 (en) 2019-04-23
UA120603C2 (uk) 2020-01-10
AU2014365665A1 (en) 2016-07-14
KR20160089518A (ko) 2016-07-27
MA39072A1 (fr) 2017-05-31
CN105813642B (zh) 2019-05-03
CN105813642A (zh) 2016-07-27
SA516371348B1 (ar) 2019-11-10
TN2016000196A1 (fr) 2017-10-06
EP3082818A1 (fr) 2016-10-26
MX2016007795A (es) 2016-09-07

Similar Documents

Publication Publication Date Title
CN111212648B (zh) 用于预防或治疗肌肉疾患的组合物和方法
CN101977596A (zh) 大麻素类的新用途
NZ570492A (en) Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
US10265322B2 (en) Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions
RU2744878C2 (ru) Ингибиторы дипептидилпептидазы-4 для местного офтальмологического лечения нейродегенеративных заболеваний сетчатки
US20200108069A1 (en) Treatment of Fibrotic Conditions
CN104736151A (zh) 纤维化的柚皮素和积雪草酸组合治疗
WO2011091461A1 (de) Verbindungen zur verwendung bei der behandlung von erkrankungen
AU2010345621B2 (en) Use of pentoxifylline for preventing or treating constipation
WO2016066789A1 (fr) Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
OA17905A (fr) Utilisation d'antagonistes PAR-1 pour la prévention et/ou le traitement des pathologies fonctionnelles pelvi-périnéales.
KR20050121324A (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 배뇨장애 치료제 및 부종 치료제조성물
AU2018344402A1 (en) New treatment of SMA
WO2020127539A1 (fr) Utilisation d'un antagoniste de par-1 pour le traitement d'une maladie inflammatoire chronique intestinale
HK1221913B (zh) Par-1拮抗剂用於预防和/或治疗骨盆-会阴功能病状的用途
EP2124956A1 (fr) Utilisation du 10-[(3r)-1-azabicyclo]2.2.2]oct-3-ylméthyl]-10h-phénothiazine pour la préparation d'un médicament exerçant une inhibition sélective des récepteurs muscariniques m1, m2 et m3
US20240293441A1 (en) New therapeutic use of type 2 iodothyronine deiodinase (d2) inhibitors
JP5478495B2 (ja) アドレナリン作動性α−１受容体アンタゴニストの新規な治療的使用
EP3773545B1 (en) Combination of 2-(4-methylphenyl) sulfonyl-5-nitrofuran with ramipril or empagliflozin for treating diabetic kidney disease.
JP2019073493A (ja) ヴルヴォディニアの治療
Kwatra et al. Therapeutic Targets and Pharmacological Interventions: An Update
Walsh Antihistamines (H1 receptor antagonists)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191009

FZDE Discontinued

Effective date: 20220503

FZDE Discontinued

Effective date: 20220503